首页> 外文期刊>Quantitative Imaging in Medicine and Surgery >Combination diagnosis with elastography strain ratio and molecular markers effectively improves the diagnosis rate of small breast cancer and lymph node metastasis
【24h】

Combination diagnosis with elastography strain ratio and molecular markers effectively improves the diagnosis rate of small breast cancer and lymph node metastasis

机译:具有弹性造影菌株和分子标记的组合诊断有效提高了小乳腺癌和淋巴结转移的诊断率

获取原文
           

摘要

Background: To evaluate the strain ratio (SR) combined with molecular pathological and serum markers for the diagnosis of breast masses. Methods: SR and 7-point scale elasticity scores were used with real-time tissue elastography and 2-dimensional color-Doppler ultrasound (US) to diagnose breast lesions in 311 hospitalized patients. Immunohistochemical staining and enzyme-linked immunosorbent assays (ELISAs) were used to examine pathological and serum tumor markers and their correlations with SR findings. Results: SR had a higher diagnostic value compared to the 7-point scale elasticity score, displaying an obvious low-to-high distribution from benign to malignant lesions with an optimal cutoff point at 3.88, which yielded an area under the curve (AUC) of 0.896 with 89.1% sensitivity, 85.6% specificity, and positive and negative predictive values of 91.0% and 82.8%, respectively. The differences of SR values between small (≤1.5 cm), large (3 cm) (P=0.010), and moderate (1.5 cm and ≤3 cm) sizes (P=0.038) in distinguishing benign from malignant breast masses were statistically significant, with SR being most specific and sensitive for diagnosing small lesions. Expression of 3 molecular pathological indicators (p75NTR, p63, and CK5/6), and 5 serum mastocarcinoma markers (uPA, PAI-I, CA27-29, CEA, and CA15-3) showed statistical significance (P0.05) in distinguishing between benign and malignant breast lesions. Furthermore, SR combined with CA15-3 and CK5/6 positivity showed 94.2% sensitivity and 89.2% specificity as combined markers for triple-negative (TN) breast cancer, whereas SR combined with D2-40 and CK19 were good diagnostic markers for breast cancer lymph node metastasis. Conclusions: SR, together with a molecular and serological marker, may serve as an additional tool for the diagnosis of small breast cancer tumors.
机译:背景:评价应变比(SR)与分子病理和血清标志物联合用于诊断乳腺菌素。方法:SR和7点刻度弹性分数与实时组织弹性造影和二维颜色多普勒超声(美国)用于诊断311名住院患者的乳腺病变。免疫组织化学染色和酶联免疫吸附试验(ELISAS)用于检查病理和血清肿瘤标志物及其与SR结果的相关性。结果:与7分尺寸弹性得分相比,SR具有更高的诊断价值,从3.88时显示出从良性到恶性病变的明显低至高度分布,在3.88处获得了最佳截止点,其在曲线下产生了一个区域(AUC) 0.896的灵敏度为89.1%,特异性为85.6%,阳性和阴性预测值分别为91.0%和82.8%。小(≤1.5cm),大(> 3cm)(p = 0.010)和中等(> 1.5cm和≤3cm)尺寸(p = 0.038),在区分恶性乳房肿块中的差异统计学意义,SR是诊断小病变的最具体和敏感。 3分子病理指标(P75NTR,P63和CK5 / 6)的表达,以及5个血清乳腺癌标志物(UPA,PAI-I,CA27-29,CEA和CA15-3)显示出统计学意义(P <0.05)在区分中在良性和恶性乳房病变之间。此外,Sr与Ca15-3和CK5 / 6阳性相结合显示了94.2%的灵敏度和89.2%的特异性为三阴性(TN)乳腺癌的组合标记,而SR与D2-40和CK19相结合,是乳腺癌的良好诊断标志物淋巴结转移。结论:SR与分子和血清学标志物一起可用作诊断小乳腺癌肿瘤的额外工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号